OncLive TV

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

Wen Wee Ma, MBBS, discusses the potential advantages of inhaled KB707 and the rationale behind investigating it in non–small cell lung cancer.

Priya Rastogi, MD, discusses a substudy evaluating a whole-exome sequencing, tumor-informed ctDNA MRD assay in TNBC after neoadjuvant chemotherapy.

Amol Akhade, MD, discusses the pharmacologic rationale for reduced-dose checkpoint inhibition and the funding barrier to definitive randomized evidence.

Narjust Florez, MD, discusses a trilingual, multidisciplinary workshop that was held at the 2026 ASCO Annual Meeting.

Amol Akhade, MD, discusses how cost shapes immunotherapy decisions and what standard cost-effectiveness measures miss for individual patients.

Narjust Florez, MD, discusses how the FDA approval of zidesamtinib in locally advanced or metastatic ROS1-positive NSCLC is an example of the fast pace of clinical oncology.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Matthew Galsky, MD, discusses safety data with perioperative enfortumab vedotin plus pembrolizumab in MIBC.

Shubham Pant, MD, MBBS, discusses data for daraxonrasib and its potential impact on pancreatic cancer management.

Sandip Patel, MD, discusses key unmet needs and open questions surrounding EGFR-mutant NSCLC that has transformed to SCLC.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.

Matthew Galsky, MD, discusses systemic therapy advances in muscle-invasive bladder cancer.

Marc S. Hoffmann, MD, discusses current data for sonrotoclax plus zanubrutinib and upcoming trials for the combination in mantle cell lymphoma.

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

Mabel Mardones, MD, discusses data for first-line giredestrant plus palbociclib in ER-positive, HER2-negative advanced breast cancer.

Eric Mou, MD, discusses efficacy data for tacabrutideg in chronic lymphocytic leukemia and what these findings may mean for the field.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Matthew Galsky, MD, discusses the FDA approval of pembrolizumab plus enfortumab vedotin in MIBC.

Daniel Ermann, MD, discusses findings from a real-world study of first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.

Hannah Kenny, MD, and Joseph M. Curry, MD, discuss findings from a phase 2 study of cemiplimab in locally advanced BCC of the head and neck.

Peter E. Fecci, MD, PhD, discusses therapeutic advances and challenges in the management of glioblastoma, and the trajectory of immunotherapy development.

Stephan Stilgenbauer, MD, discusses efficacy data for tacabrutideg from CaDAnCe-101 and how it will inform future CLL research.

Daniel Ermann, MD, discusses data for real-world treatment burdens among older patients with chronic lymphocytic leukemia.

Andrew Ko, MD, details the safety profile of Optune Pax in the PANOVA-3 trial for patients with locally advanced pancreatic cancer.

Daniel Ermann, MD, discusses improvements shown in real-world data for zanubrutinib compared with acalabrutinib in treatment-naive CLL.

Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.

Toni Choueiri, MD, discusses data from LITESPARK-022 in ccRCC.